ENLV
Enlivex Therapeutics Ltd.
$1.06
+$0.01(+0.99%)
72
Overall
--
Value
72
Tech
--
Quality
Market Cap
$25.76M
Volume
74.84K
52W Range
$0.81 - $2.10
Target Price
$10.00
Order:
Income Statement
| Metric | Trend | Chart | 2014 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $-126.0K | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | -- | -- | -- | $126.0K | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-7.1M | $-15.9M | $-2.2M | $5.3M | $8.6M | $9.8M | $19.3M | $-25.8M | $25.8M | $29.4M | ||
| Research & Development | $4.4M | $8.9M | $1.7M | $4.3M | $5.6M | $6.1M | $12.9M | $18.7M | $18.7M | $19.0M | ||
| Research Expense | $4.4M | $8.9M | $1.7M | $4.3M | $5.6M | $6.1M | $12.9M | $18.7M | $9.6M | -- | ||
| Selling, General & Administrative | $2.6M | $7.0M | $480.0K | $1.0M | $3.0M | $3.7M | $6.4M | $7.1M | $7.1M | $6.1M | ||
| Selling & Marketing Expenses | -- | $1.1M | $479.0K | -- | -- | -- | -- | -- | $14.0K | -- | ||
| General & Administrative Expenses | $2.6M | $5.9M | $480.0K | $1.0M | $3.0M | $3.7M | $6.4M | $7.1M | $7.1M | $6.1M | ||
| Salaries & Wages | $-736.0K | $-700.0K | $-365.0K | $-1.0M | $-810.0K | $-670.0K | $-2.9M | $-2.7M | $8.2M | -- | ||
| Depreciation & Amortization | $-5.0K | $-38.0K | $-83.0K | $-121.0K | $-206.0K | $-286.0K | $-546.0K | $-777.0K | $802.0K | -- | ||
| Depreciation & Amortization | $-5.0K | $-38.0K | $-83.0K | $-121.0K | $-206.0K | $-286.0K | $-546.0K | $-777.0K | $802.0K | -- | ||
| Other Operating Expenses | -- | -- | $-24.0K | $-57.0K | $-484.0K | $-253.0K | $-367.0K | $-707.0K | $2.8M | $4.2M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-7.1M | $-15.9M | $-2.2M | $-5.3M | $-8.6M | $-9.8M | $-19.3M | $-25.8M | $-25.8M | $-29.4M | ||
| EBITDA | $-7.0M | $-15.8M | $-2.4M | $-4.1M | $-9.2M | $-11.5M | $-13.9M | $-30.3M | -- | -- | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $58.0K | $60.0K | $37.0K | $138.0K | $238.0K | $225.0K | $120.0K | $835.0K | $1.6M | -- | ||
| Net Non-Operating Interest Income/Expense | $58.0K | $60.0K | $37.0K | $138.0K | $238.0K | $225.0K | $120.0K | $835.0K | $1.6M | -- | ||
| Gain on Sale of Securities | -- | -- | -- | $132.0K | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $-85.0K | $-8.0K | $333.0K | $-1.1M | $765.0K | $2.0M | $-4.8M | $5.3M | $-5.3M | $-327.0K | ||
| Other Special Charges | $85.0K | $8.0K | $-333.0K | $1.1M | $-765.0K | $-2.0M | $4.8M | $-5.3M | $5.3M | $327.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-34.0K | $-65.0K | $-36.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $34.0K | $65.0K | $36.0K | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-7.0M | $-15.8M | $-2.5M | $-4.2M | $-9.4M | $-11.8M | $-14.5M | $-31.1M | -- | -- | ||
| Pre-Tax Income | $-7.0M | $-15.8M | $-2.5M | $-4.2M | $-9.4M | $-11.8M | $-14.5M | $-31.1M | $-20.5M | $-29.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $216.0K | $-601.0K | $-976.0K | $-2.2M | $-2.7M | $-1.1M | $-522.0K | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-7.0M | $-16.0M | $-2.5M | $-4.2M | $-9.4M | $-11.8M | $-14.5M | $-31.1M | $-20.5M | $-29.1M | ||
| Net Income (Continuing Operations) | $-7.0M | $-16.0M | $-2.5M | $-4.2M | $-9.4M | $-11.8M | $-14.5M | $-31.1M | $-20.5M | $-29.1M | ||
| Net Income (Discontinued Operations) | $-7.0M | $-16.0M | $-2.5M | $-4.2M | $-9.4M | $-11.8M | $-14.5M | $-31.1M | $-20.5M | $-29.1M | ||
| Net Income (Common Stockholders) | $-7.0M | $-16.0M | $-2.5M | $-4.2M | $-9.4M | $-11.8M | $-14.5M | $-31.1M | $-20.5M | $-29.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-7.1M | $-15.9M | $-2.2M | $5.3M | $8.6M | $9.8M | $19.2M | $-25.8M | $25.8M | $29.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.5M | $2.0M | $414.2K | $438.7K | $8.6M | $13.2M | $17.9M | $18.4M | $18.4M | $18.6M | ||
| Average Shares Outstanding (Diluted) | $1.5M | $2.0M | -- | $438.7K | $8.6M | $13.2M | $17.9M | $18.4M | $18.4M | $18.6M | ||
| Shares Outstanding | $355.8K | $409.8K | $417.8K | $52.5K | $10.3M | $14.6M | $18.3M | $18.4M | $23.8M | $23.8M | ||
| Basic EPS | -- | -- | -- | -- | -- | -- | $-0.81 | $-1.69 | $-1.69 | $-1.56 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-0.81 | -- | $-1.69 | $-1.56 | ||
| Diluted EPS | $-4.56 | $-8.08 | -- | $-11.2 | $-1.11 | $-0.90 | $-0.81 | $-1.69 | $-1.69 | $-1.56 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-11.2 | $-1.11 | $-0.90 | -- | -- | $-1.69 | $-1.56 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | $-1.2M | $-1.9M | $-5.5B | -- | -- | -- | -- | -- | ||
| Acquisition Expense | -- | -- | -- | -- | -- | -- | -- | -- | $911.0K | -- | ||
| Commission Expenses | -- | -- | -- | -- | -- | -- | -- | -- | $14.0K | -- | ||
| Development Expense | -- | -- | -- | -- | $-1.1M | $-1.2M | $-1.0M | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | $13.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Insurance And Claims | -- | -- | -- | -- | -- | -- | -- | -- | $567.0K | -- | ||
| Marketing Expense | -- | $1.1M | $479.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $2.6M | $5.9M | $480.0K | $1.0M | $3.0M | $3.7M | $6.4M | $7.1M | $7.1M | $6.1M | ||
| Otherunder Preferred Stock Dividend | -- | -- | $-1.2M | $-1.9M | $-5.5B | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | $-1.2M | $-1.9M | $-5.5B | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $2.6M | $5.9M | $480.0K | -- | -- | -- | -- | $7.1M | -- | -- | ||
| Restruct | $-34.0K | $-65.0K | $-36.0K | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENLV | $1.06 | +1.0% | 74.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enlivex Therapeutics Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW